Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Microbot Medical ( (MBOT) ).
On March 24, 2026, Microbot Medical announced that results from its ACCESS-PVI pivotal study of the LIBERTY Endovascular Robotic System have been published in the Journal of Vascular and Interventional Radiology. The multicenter feasibility study, completed in 2025 and led by interventional radiologist Dr. Francois Cornelis, evaluates a disposable, remotely operated robotic system for arterial peripheral vascular interventions.
Publication in JVIR, a leading peer-reviewed journal for interventional radiologists, marks an important validation step, confirming that the study’s methodology and data have undergone rigorous independent review. Coming after the LIBERTY system’s U.S. FDA clearance in September 2025 and ahead of its planned full market launch at the Society of Interventional Radiology conference in April 2026, the paper strengthens the device’s clinical credibility and supports Microbot’s push for broader commercial adoption.
The most recent analyst rating on (MBOT) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Microbot Medical stock, see the MBOT Stock Forecast page.
More about Microbot Medical
Microbot Medical Inc. is a commercial-stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Its flagship product, the LIBERTY Endovascular Robotic System, is the world’s first FDA-cleared, single-use, remotely operated robotic solution designed to enhance precision, efficiency and safety in peripheral endovascular care.
Backed by a sizable intellectual property portfolio, Microbot targets interventional radiologists and vascular specialists seeking minimally invasive, image-guided treatments. The company is positioning LIBERTY as a disruptive tool in endovascular robotics, aiming to reduce radiation exposure and physical strain for clinicians while supporting broader adoption through clinical evidence.
Average Trading Volume: 1,974,838
Technical Sentiment Signal: Hold
Current Market Cap: $169.2M
For a thorough assessment of MBOT stock, go to TipRanks’ Stock Analysis page.